Business
Rapport Therapeutics to Present Data at American Epilepsy Society Annual Meeting
Poster presentations on Phase 2a trial seizure biomarker, preclinical, and Phase 1 clinical data BOSTON and SAN DIEGO, Nov. 14, 2024 (GLOBE NEWSWIRE) --
About this update from Rapport Therapeutics, Inc.
[{"type":"text","content":"Poster presentations on Phase 2a trial seizure biomarker, preclinical, and Phase 1 clinical data\nBOSTON and SAN DIEGO, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP), a clinical-stage biotechnology company dedicated to the discovery and development of small molecule precision medicines for patients suffering from central nervous system (CNS) disorders, today announced multiple presentations at the upcoming American Epilepsy Society Annual Meeting, taking place December 6-10, 2024, in Los Angeles. Using analysis from an open-label, long-term treatment study of the RNS® System, Rapport will present key new data on the correlation between the reduction in long episode (LE) frequency (abnormal electrographic activity) and clinically meaningful reduction ( 50%) in patient reported seizures. The LE biomarker is being used in the Company’s novel Phase 2a proof-of-concept trial of lead product candidate RAP-219 as a potential anti-seizure treatment for patients with drug-resistant focal epilepsy. The Phase 2a trial measures LE frequency reduction in patients who have an implanted responsive neurotransmitter device (RNS® System) in response to RAP-219 treatment, demonstrating expected reduced clinical seizure frequency. The full schedule of Rapport posters at AES is as follows: Date & LocationPoster TitlePresenterSaturday, Dec. 07, 2024, 12:00 – 6:00 p.m. PSTSouth Hall H, Level 1Antiseizure Effects with Selective TARPγ8 Negative Allosteric Modulators in Preclinical Seizure Models (Poster #390)Jose Matta, PhD; Brock Shireman, PhD; Laurie Volak, PhD; Michael Maher, PhD; David Bredt, MD, PhDSaturday, Dec. 07, 2024, 12:00 – 6:00 p.m. PSTSouth Hall H, Level 1Impact of Food on the PK and Tolerability of RAP-219 in Healthy Volunteers (Poster #409)Stephen Greene, PharmD; Swamy Yeleswaram, PhDSaturday, Dec. 07, 2024, 12:00 – 6:00 p.m. PSTSouth Hall H, Level 1Optimal Cut Point for Reduction in Long Episode Frequency to Predict Meaningful Change in Clinical Seizure Frequency (Poster #494)Arnold R Gammaitoni, PharmD, Martha J. Morrell, MD, Jacqueline A French, MD, Daniel Friedman, MD, Kathryn A Davis, MD, Thomas K Tcheng, PhD, Cairn Seale, MS, Bradley S Galer, MD, William W Motley, MDSunday, Dec. 08, 2024, 10:00 – 4:00 p.m. PSTSouth Hall H, Level 1Safety, Tolerability, and Pharmacokinetics of RAP-219 in Healthy Voluntee...